Community Academic Profiles–

Sandra Horning

Back to Profile

Publication Details

  • Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

    Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. J Clin Oncol. 2009; 27 (10): 1607-14

    To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma.

    PubMedID: 19255334

Stanford Medicine Resources:

Footer Links: